Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Escalating Phase I, Healthy Subjects Study of Intravenous OPN‐305, a Humanized Anti‐TLR2 Antibody

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 5, 2013-11 ,pp. : 593-600

John Wiley & Sons Inc

Access to resources Recommend Favorite

Effect of Nebulized Beclomethasone on Airway Inflammation and Clinical Status of Children with Allergic Asthma and Rhinitis: A Randomized, Double-Blind, Placebo-Controlled Study

By  

International Archives of Allergy and Immunology, Vol. 161, Iss. 1, 2012-12 ,pp. : 53-64

Karger

Access to resources Recommend Favorite

Efficacy and safety of fasiglifam (TAK‐875), a G protein‐coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double‐blind, placebo‐controlled, phase III trial

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 675-681

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Effect of Desloratadine on Eosinophil/Basophil Progenitors and Other Inflammatory Markers in Seasonal Allergic Rhinitis: A Placebo-Controlled Randomized Study

By  

International Archives of Allergy and Immunology, Vol. 138, Iss. 3, 2005-10 ,pp. : 209-216

Karger

Access to resources Recommend Favorite

A DOUBLE‐BLIND, RANDOMIZED, PLACEBO‐CONTROLLED, FIXED‐DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER

By  

DEPRESSION AND ANXIETY (ELECTRONIC), Vol. 32, Iss. 6, 2015-06 ,pp. : 451-459

John Wiley & Sons Inc

Access to resources Recommend Favorite